SLC5A2 and heart failure: A recent animal study showed that there is a decrease in the Firmicutes/Bacteroidetes ratio in heart-failure-induced mice that have been treated with dapagliflozin, an SGLT-2 inhibitor, resulting in reduced inflammation and cardiac fibrosis in mice.